GlassScriptPhysician profile
Daniel Francis Klee
NPI 1225013824
$9,154.88
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,109 · 2020: $1,868 · 2021: $2,056 · 2022: $2,537 · 2023: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $775.51 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $757.34 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $688.49 | 2019-2022 | |
| Abbott Laboratories | $597.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $518.10 | 2019-2023 | Brilinta |
| Edwards Lifesciences Corporation | $467.54 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $457.32 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $412.87 | 2019-2022 | |
| Amgen INC. | $402.00 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $336.67 | 2019-2023 | |
| Astellas Pharma US INC | $304.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.07 | 2019-2023 | Jardiance |
| Philips North America LLC | $257.43 | 2022-2023 | |
| Heartflow, INC. | $243.40 | 2022-2023 | Ffrct |
| Irhythm Technologies, INC. | $224.58 | 2019-2023 | Zio Xt Patch |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Klee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.